Supporting Information for

A Hg(OTf)₂-Catalyzed Enolate Umpolung Reaction Enables the Synthesis of Coumaran-3-ones and Indolin-3-ones

Zhouting Rong,* Weican Hu, Ning Dai and Guoying Qian*

College of Biological and Environmental Sciences, Zhejiang Wanli University, Ningbo 315100, People's Republic of China

Table of Contents

1. General Methods	2
2. Procedure for the preparation of substrates	2
3. Procedure for the synthesis of coumaran-3-ones and indolin-3-ones	
4. Procedure for the preparation of compounds 7a-d and 8a'-d'	17
5. References	19
6. ¹ H NMR and ¹³ C NMR Spectra	20


1. General Methods.

All reactions were carried out in solvents dried using a Solvent Purification System (SPS). Thin layer chromatography was carried out using TLC aluminum sheets coated with 0.2 mm of silica gel (Merck Gf234). Chromatographic purifications were carried out using flash grade silica gel (SDS Chromatogel 60 ACC, 40-60 μm). NMR spectra were recorded at 23 °C on Bruker Avance 400 Ultrashield apparatus (400 MHz, CDCl₃ as solvent). Mass spectra were recorded on a Waters LCT Premier Spectrometer (ESI). Infrared spectra of **2d** and **6i** were recorded on a Nicolet AVATER FTIR330 spectrometer as thin film and are reported in reciprocal centimeter (cm⁻¹). IR data of other products have been reported in previous publications.¹

Note 1: The NMR spectra of compounds **2a**, **8a'-c'** were calibrated to 7.26 ppm (CHCl₃ in CDCl₃). All other compounds were calibrated to 0 ppm (TMS in CDCl₃).

Note 2: Warning! $Hg(OTf)_2$ and the organomercury intermediates generated during the reactions might be toxic. Please take special care when operating reactions and disposing mercury containing waste.


2. Procedures for the preparation of substrates.



General procedure A: Pd(PPh₃)₂Cl₂ (0.06 mmol), CuI (0.12 mmol) and Et₃N (9 mmol) were added sequentially to a solution of 2-iodophenol (3 mmol) and trimethylsilylacetylene (4.5 mmol) in THF (10 mL) at 23 °C and the mixture was stirred at this temperature for 3 h before it was quenched with saturated aqueous NH₄Cl (10 mL). The aqueous layer was extracted with Et₂O (10 mL) and the combined organic layer was washed sequentially with 0.1 N HCl (10 mL), water (10 mL) and brine (10 mL), dried over anhydrous Na₂SO₄. The solvent was evaporated and the residue was dissolved in THF (15 mL) and tetrabutylammonium fluoride (4.5 mL, 1.0 M in THF, 4.5 mmol) was added dropwise. The reaction mixture was then stirred at 23 °C for 1 h before it was quenched with saturated aqueous NH₄Cl (15 mL). The aqueous layer was extracted with Et₂O and the combined organic layer was washed sequentially with saturated aqueous NH₄Cl (15 mL). The solvent was evaporated and the residue was extracted with Et₂O and the combined organic layer was washed sequentially with water (10 mL) and brine (10 mL), dried over anhydrous Na₂SO₄. The solvent was evaporated and the residue was extracted with Et₂O and the combined organic layer was washed sequentially with water (10 mL) and brine (10 mL), dried over anhydrous Na₂SO₄. The solvent was evaporated and the residue was purified by flash column chromatography (hexane/EtOAc=10/1) to give 2-ethynylphenol. Substrates **1b**, **1g** and **1h** were synthesized using general procedure A.

$$R + OH \qquad \begin{array}{c} 1) \operatorname{CBr}_4, \operatorname{PPh}_3 \\ CH_2 \operatorname{Cl}_2, 0 \ {}^\circ \operatorname{C}, 2 \ h \\ \hline \\ 2) \ n \cdot \operatorname{BuLi}, \ THF, \ -78 \ {}^\circ \operatorname{C}, 1 \ h \end{array} \qquad R + OH \qquad \begin{array}{c} \\ \end{array}$$

General procedure B: To a stirred solution of salicylaldehyde (10 mmol) and carbon tetrabromide (20 mmol) in dichloromethane (10 mL) was added triphenylphosphine (40 mmol) in portions over a period of 20 minutes at 0 °C temperature. The reaction mixture was allowed to stir at 0 $\,^{\circ}$ C temperature for 2 h before it was quenched with water (15 mL). The reaction mixture was extracted with dichloromethane (2 x 20 mL) and the organic layers were washed with brine (10 mL). The organic layers were dried over anhydrous Na₂SO₄ and the solvent was evaporated under reduced pressure and the residue was purified by flash column chromatography (hexane/EtOAc=10/1) to give product. The product was then dissolved in THF (40 mL) and n-BuLi (15 mL, 2.0 M in hexanes, 30 mmol) was added dropwise at -78 °C and the mixture was stirred at -78 °C for 1 h before it was quenched with saturated aqueous NH₄Cl (50 mL). The aqueous layer was extracted with Et₂O (50 mL) and the combined organic layer was washed sequentially with water (50 mL) and brine (50 mL), dried over anhydrous Na₂SO₄. The solvent was evaporated and the residue was purified by flash column chromatography (hexane/EtOAc=10/1) to give 2-ethynylphenol. Substrates 1c, 1d, 1e, 1f, 1i, 1j, 1k and 1l were synthesized using general procedure B.




General procedure C: Pd(PPh₃)₂Cl₂ (0.06 mmol), CuI (0.12 mmol) and Et₃N (9 mmol) were added sequentially to a solution of 2-iodoaniline (3 mmol) and trimethylsilylacetylene (4.5 mmol) in THF (10 mL) at 23 °C and the mixture was stirred at this temperature for 3 h before it was guenched with saturated aqueous NH₄Cl (10 mL). The aqueous layer was extracted with Et₂O (10 mL) and the combined organic layer was washed sequentially with 0.1 N HCl (10 mL), water (10 mL) and brine (10 mL), dried over anhydrous Na₂SO₄. The solvent was evaporated and the residue was dissolved in THF (15 mL) and tetrabutylammonium fluoride (4.5 mL, 1.0 M in THF, 4.5 mmol) was added dropwise. The reaction mixture was then stirred at 23 °C for 1 h before it was quenched with saturated aqueous NH₄Cl (15 mL). The aqueous layer was extracted with Et₂O and the combined organic layer was washed sequentially with water (10 mL) and brine (10 mL), dried over anhydrous Na₂SO₄. The solvent was evaporated and the residue was purified by flash column chromatography (hexane/EtOAc=5/1) to give 2-ethynylaniline which was dissolved in dichloromethane (3 mL). Tosyl chloride (3.6 mmol) and pyridine (12 mmol) was added and the mixture was stirred at 23 °C for 3 h before it was quenched with saturated aqueous NH₄Cl (5 mL). The aqueous layer was extracted with dichloromethane (5 mL) and the combined organic layer was washed sequentially with 0.1 N HCl (5 mL), water (5 mL) and brine (5 mL), dried over anhydrous Na₂SO₄. The solvent was evaporated and the residue was purified by flash column

chromatography (hexane/EtOAc=3/1) to give *N*-tosyl-2-ethynylaniline. Substrates **5ai** were synthesized using general procedure C.



Substrate 1a was purchased from commercial sources and used without purification.

¹**H** NMR (400 MHz, CDCl₃) δ 7.37 (dd, J = 7.5, 1.5 Hz, 1H), 7.27 (td, J = 7.5, 1.5 Hz, 1H), 6.93 (d, J = 8.0 Hz, 1H), 6.86 (t, J = 8.0 Hz, 1H), 5.89 (s, 1H), 3.45 (s, 1H). The data is in accordance with the literature.²




333 mg, overall yield: 84%, colorless oil.

¹**H** NMR (400 MHz, CDCl₃) δ 7.21 (d, J = 2.2 Hz, 1H), 7.14 – 7.06 (m, 1H), 6.87 (d, J = 8.3 Hz, 1H), 5.73 (s, 1H), 3.46 (s, 1H), 2.28 (s, 3H).


¹³C NMR (101 MHz, CDCl₃) δ 155.3, 132.1, 131.7, 129.6, 114.7, 107.9, 83.9, 78.6, 20.3.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₉H₉O 133.0653; Found 133.0655.



581 mg, overall yield: 44%, colorless oil.

¹**H** NMR (400 MHz, CDCl₃) δ 7.25 (d, J = 8.0 Hz, 1H), 6.76 (s, 1H), 6.67 (d, J = 7.5 Hz, 1H), 5.75 (s, 1H), 3.41 (s, 1H), 2.31 (s, 3H). The data is in accordance with the literature.²



¹**H NMR** (400 MHz, CDCl₃) δ 7.25 (dd, J = 7.7, 1.6 Hz, 1H), 7.15 (ddt, J = 7.5, 1.7, 0.9 Hz, 1H), 6.80 (t, J = 7.6 Hz, 1H), 5.89 (s, 1H), 3.48 (s, 1H), 2.28 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 155.6, 132.2, 129.4, 124.1, 119.9, 107.6, 84.0, 78.7, 15.9.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₉H₉O 133.0653; Found 133.0651.




725 mg, overall yield: 49%, colorless oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.05 (dd, J = 7.7, 1.6 Hz, 1H), 6.89 (dd, J = 8.1, 1.5 Hz, 1H), 6.85 – 6.80 (m, 1H), 6.01 (s, 1H), 3.92 (s, 3H), 3.38 (s, 1H).

¹³**C NMR** (101 MHz, CDCl₃) δ 147.6, 146.6, 125.0, 119.8, 111.7, 108.5, 82.0, 78.9, 56.1.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₉H₉O₂ 149.0603; Found 149.0606.



¹**H NMR** (400 MHz, CDCl₃) δ 6.92 – 6.90 (m, 1H), 6.89 (d, J = 1.2 Hz, 2H), 5.54 (s, 1H), 3.77 (s, 3H), 3.47 (s, 1H).


¹³C NMR (101 MHz, CDCl₃) δ 152.9, 151.7, 118.0, 115.8, 115.7, 108.3, 84.0, 78.5, 55.8.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₉H₉O₂ 149.0603; Found 149.0608.




326 mg, overall yield: 80%, colorless oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.08 (dd, J = 8.4 Hz, 2.8 Hz, 1H), 7.04 – 6.96 (m, 1H), 6.90 (dd, J = 9.0 Hz, 4.8 Hz, 1H), 5.66 (s, 1H), 3.50 (s, 1H). The data is in accordance with the literature.³



¹**H NMR** (400 MHz, CDCl₃) δ 7.33 (d, J = 2.4 Hz, 1H), 7.21 (dd, J = 8.8, 2.4 Hz, 1H), 6.88 (d, J = 8.8 Hz, 1H), 5.79 (s, 1H), 3.48 (s, 1H). The data is in accordance with the literature.²



687 mg, overall yield: 45%, colorless oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.44 (d, J = 2.0 Hz, 1H), 7.29 (d, J = 8.3 Hz, 1H), 6.92 (dd, J = 8.3, 2.0 Hz, 1H), 5.76 (s, 1H), 3.45 (s, 1H). The data is in accordance with the literature.⁴




595 mg, overall yield: 39%, colorless oil.

¹**H NMR** (400 MHz, CDCl₃) δ 7.21 (t, J = 8.2 Hz, 1H), 7.00 (dd, J = 8.0, 1.0 Hz, 1H), 6.90 (dd, J = 8.3, 1.0 Hz, 1H), 5.96 (s, 1H), 3.78 (s, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 158.5, 135.8, 130.7, 121.1, 113.1, 109.2, 89.0, 75.4.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₆H₆ClO 153.0107; Found 153.0104.




505 mg, overall yield: 31%, light yellow solid.


¹**H NMR** (400 MHz, CDCl₃) δ 8.34 (d, J = 2.8 Hz, 1H), 8.20 (dd, J = 9.1, 2.8 Hz, 1H), 7.08 (d, J = 9.1 Hz, 1H), 3.61 (s, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 162.3, 141.1, 128.3, 126.7, 115.5, 109.2, 86.4, 76.1.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₈H₆NO₃ 164.0348; Found 164.0344.




¹**H** NMR (400 MHz, CDCl₃) δ 8.75 (dq, J = 8.3, 0.9 Hz, 1H), 8.04 (d, J = 9.0 Hz, 1H), 7.89 (dt, J = 8.2, 0.9 Hz, 1H), 7.75 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H), 7.54 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H), 7.32 – 7.29 (m, 1H), 5.73 (s, 1H), 3.43 (s, 1H). The data is in accordance with the literature.⁵



¹**H NMR** (400 MHz, CDCl₃) δ 7.73 – 7.69 (m, 2H), 7.61 (dd, J = 8.4, 1.1 Hz, 1H), 7.36 (dd, J = 7.7, 1.5 Hz, 1H), 7.34 – 7.28 (m, 1H), 7.26 (s, 1H), 7.24 (d, J = 8.1 Hz, 2H), 7.03 (td, J = 7.6, 1.1 Hz, 1H), 3.39 (s, 1H), 2.39 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 144.1, 138.5, 135.9, 132.5, 130.2, 129.7, 127.4, 124.2, 119.3, 112.7, 84.4, 78.6, 21.6.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{15}H_{13}NNaO_2S$ 294.0565; Found 294.0569.




599 mg, overall yield: 70%, light yellow solid.

¹**H NMR** (400 MHz, CDCl₃) δ 7.72 – 7.65 (m, 2H), 7.51 (d, J = 8.3 Hz, 1H), 7.22 (d, J = 8.0 Hz, 2H), 7.18 – 7.08 (m, 3H), 3.32 (s, 1H), 2.38 (s, 3H), 2.24 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 144.0, 136.0, 135.9, 134.2, 132.8, 131.0, 129.6, 127.4, 119.96, 113.0, 83.8, 78.8, 21.6, 20.5.


HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{16}H_{15}NNaO_2S$ 308.0723; Found 308.0728.



¹**H NMR** (400 MHz, CDCl₃) δ 7.74 – 7.68 (m, 2H), 7.46 – 7.42 (m, 1H), 7.26 – 7.18 (m, 4H), 6.83 (ddd, J = 7.9, 1.7, 0.8 Hz, 1H), 3.34 (s, 1H), 2.36 (s, 3H), 2.32 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 144.1, 140.8, 138.3, 136.0, 132.2, 129.6, 127.3, 125.2, 120.1, 109.9, 83.8, 78.8, 21.8, 21.6.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for C₁₆H₁₅NNaO₂S 308.0723; Found 308.0729.




686 mg, overall yield: 76%, brown solid.

¹**H** NMR (400 MHz, CDCl₃) δ 7.65 – 7.60 (m, 2H), 7.56 (d, J = 9.0 Hz, 1H), 7.24 – 7.19 (m, 2H), 6.90 (dd, J = 9.0, 3.0 Hz, 1H), 6.84 (d, J = 3.0 Hz, 1H), 3.76 (s, 3H), 3.25 (s, 1H), 2.39 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 156.5, 143.9, 135.8, 131.5, 129.5, 127.4, 123.2, 116.7, 116.6, 115.2, 83.6, 78.7, 55.5, 21.6.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for C₁₆H₁₅NNaO₃S 324.0672; Found 324.0678.




512 mg, overall yield: 59%, yellow solid.

¹**H** NMR (400 MHz, CDCl₃) δ 7.67 – 7.64 (m, 2H), 7.61 (ddt, J = 9.1, 5.1, 1.2 Hz, 1H), 7.25 – 7.21 (m, 2H), 7.10 (s, 1H), 7.04 (td, J = 8.4, 2.3 Hz, 2H), 3.37 (s, 1H), 2.39 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 159.0 (d, J = 246.4 Hz), 144.3, 135.6, 134.7 (d, J = 3.0 Hz), 129.7, 127.4, 122.5 (d, J = 9.1 Hz), 118.9 (d, J = 24.2 Hz), 117.5 (d, J = 22.2 Hz), 115.1 (d, J = 10.1 Hz), 85.0, 77.6 (d, J = 3.0 Hz), 21.6.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for C₁₅H₁₂FNNaO₂S 312.0472; Found 312.0477.




569 mg, overall yield: 62%, brown solid.

¹**H** NMR (400 MHz, CDCl₃) δ 7.71 – 7.67 (m, 2H), 7.57 (d, J = 8.9 Hz, 1H), 7.33 (d, J = 2.4 Hz, 1H), 7.30 – 7.23 (m, 4H), 3.42 (s, 1H), 2.41 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 144.4, 137.1, 135.6, 132.0, 130.4, 129.8, 129.5, 127.0, 120.7, 114.3, 85.4, 77.4, 21.6.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{15}H_{12}CINNaO_2S$ 328.0174; Found 328.0178.




597 mg, overall yield: 65%, brown solid.

¹**H** NMR (400 MHz, CDCl₃) δ 7.77 – 7.71 (m, 2H), 7.64 (d, J = 2.0 Hz, 1H), 7.31 – 7.26 (m, 4H), 7.01 (dd, J = 8.3, 2.0 Hz, 1H), 3.45 (s, 1H), 2.41 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 144.5, 139.5, 136.2, 135.6, 133.3, 129.8, 127.3, 124.3, 119.3, 110.7, 85.3, 77.7, 21.6.


HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{15}H_{12}CINNaO_2S$ 328.0174; Found 328.0179.



¹**H NMR** (400 MHz, CDCl₃) δ 7.72 – 7.67 (m, 2H), 7.51 (d, J = 8.8 Hz, 1H), 7.47 (d, J = 2.3 Hz, 1H), 7.41 (dd, J = 8.8, 2.3 Hz, 1H), 7.26 (d, J = 8.1 Hz, 2H), 7.21 (s, 1H), 3.44 (s, 1H), 2.40 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 144.4, 137.6, 135.6, 134.9, 133.2, 129.8, 127.3, 120.8, 116.8, 114.5, 85.6, 77.2, 21.6.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{15}H_{12}BrNNaO_2S$ 371.9671; Found 371.9676.




543 mg, overall yield: 55%, yellow solid.

¹**H** NMR (400 MHz, CDCl₃) δ 8.04 (d, J = 2.0 Hz, 1H), 7.94 (dd, J = 8.7, 2.0 Hz, 1H), 7.78 – 7.74 (m, 2H), 7.63 (d, J = 8.7 Hz, 1H), 7.28 – 7.24 (m, 2H), 3.88 (s, 3H), 3.51 (s, 1H), 2.38 (s, 3H).


¹³C NMR (101 MHz, CDCl₃) δ 165.6, 144.6, 142.2, 135.6, 134.1, 131.4, 129.9, 127.3, 125.5, 117.2, 111.7, 85.5, 77.6, 52.2, 21.6.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₁₇H₁₆NO₄S 330.0803; Found 330.0807.

3. Procedure for the synthesis of coumaran-3-ones and indolin-3-ones




General procedure: 2-Cl-pyridine *N*-oxide (77.7 mg, 0.6 mmol) and Hg(OTf)₂ (12.5 mg, 0.025 mmol) were added sequentially to a solution of 2-ethynyl phenol (or 2-ethynyl tosylaniline, 0.5 mmol) in CH₂Cl₂ (2 mL) and the mixture was stirred at 23 °C for 1 h. Then CH₂Cl₂ (10 ml) was added and the resulting mixture was washed sequentially with 0.1 N HCl (10 mL), water (10 mL) and brine (10 mL), dried over anhydrous Na₂SO₄. The solvent was evaporated and the residue was purified by flash column chromatography (hexane/EtOAc) to give the corresponding coumaran-3-one (or indolin-3-one). Note: 0.05 mmol of Hg(OTf)₂ and 3 h of reaction time were needed for 2-ethynyl tosylanilines.



¹**H NMR** (500 MHz, CDCl₃) δ 7.68 (dd, J = 7.7, 1.4 Hz, 1H), 7.62 (ddd, J = 8.5, 7.2, 1.5 Hz, 1H), 7.15 (d, J = 8.4 Hz, 1H), 7.12 – 7.07 (m, 1H), 4.63 (s, 2H).

¹³C NMR (126 MHz, CDCl₃) δ 199.9, 174.0, 137.9, 124.1, 122.0, 121.2, 113.7, 74.7.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₈H₇O₂ 135.0448; Found 135.0444.




65.9 mg, 89%, white solid.

¹**H** NMR (400 MHz, CDCl₃) δ 7.49 – 7.40 (m, 2H), 7.04 (dd, J = 8.4, 2.0 Hz, 1H), 4.66 – 4.58 (m, 2H), 2.37 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 200.0, 172.5, 139.2, 131.6, 123.4, 121.0, 113.2, 74.96, 20.6.


HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₉H₉O₂ 149.0604; Found 149.0609.



¹**H NMR** (400 MHz, CDCl₃) δ 7.56 (d, J = 7.9 Hz, 1H), 6.95 (dt, J = 1.5, 0.8 Hz, 1H), 6.92 (dd, J = 7.9, 1.2 Hz, 1H), 4.62 (s, 2H), 2.45 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 199.2, 174.6, 150.0, 123.6, 123.6, 118.8, 113.6, 74.95, 22.5.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₉H₉O₂ 149.0604; Found 149.0610.




62.9 mg, 85%, white solid.

¹**H NMR** (400 MHz, CDCl₃) δ 7.57 – 7.48 (m, 1H), 7.44 (dt, J = 7.3, 1.1 Hz, 1H), 7.02 (t, J = 7.5 Hz, 1H), 4.66 (s, 2H), 2.35 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 200.4, 172.8, 138.2, 123.8, 121.9, 121.3, 120.6, 74.70, 14.2.

IR (neat): 2930, 1710, 1618, 1492, 1422, 1288, 1130, 815, 726.


HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₉H₉O₂ 149.0604; Found 149.0606.



69.7 mg, 85%, white solid.

¹**H NMR** (400 MHz, CDCl₃) δ 7.24 (dd, J = 7.7, 1.2 Hz, 1H), 7.10 (dd, J = 7.9, 1.2 Hz, 1H), 7.01 (t, J = 7.8 Hz, 1H), 4.66 (s, 2H), 3.95 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 199.7, 164.0, 146.8, 122.5, 122.4, 118.3, 115.1, 75.1, 56.2.



¹**H** NMR (400 MHz, CDCl₃) δ 7.26 (dd, J = 9.0, 2.8 Hz, 1H), 7.10 – 7.06 (m, 2H), 4.65 (s, 2H), 3.82 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 200.1, 169.4, 155.0, 127.9, 121.1, 114.5, 103.8, 75.46, 55.9.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₉H₈NaO₃ 187.0373; Found 187.0379.




68.4 mg, 90%, white solid.

¹**H NMR** (400 MHz, CDCl₃) δ 7.39 – 7.30 (m, 2H), 7.14 – 7.09 (m, 1H), 4.68 (s, 2H).

¹³C NMR (101 MHz, CDCl₃) δ 199.3, 170.2, 157.8 (d, J = 244.4 Hz), 125.6 (d, J = 26.3 Hz), 121.6 (d, J = 8.1 Hz), 114.8 (d, J = 8.1 Hz), 109.1 (d, J = 24.2 Hz), 75.7.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for C₈H₅FNaO₂ 175.0173; Found 175.0179.




80.9 mg, 96%, white solid.

¹**H** NMR (400 MHz, CDCl₃) δ 7.65 – 7.60 (m, 1H), 7.55 (dd, J = 8.8, 2.4 Hz, 1H), 7.10 (d, J = 8.8 Hz, 1H), 4.67 (s, 2H).

¹³C NMR (101 MHz, CDCl₃) δ 198.4, 172.2, 137.7, 127.6, 123.5, 122.3, 115.0, 75.4.


HRMS (ESI) m/z: $[M + Na]^+$ Calcd for C₈H₅ClNaO₂ 190.9875; Found 190.9871.



¹**H NMR** (400 MHz, CDCl₃) δ 7.62 (d, J = 8.2 Hz, 1H), 7.19 (d, J = 1.6 Hz, 1H), 7.10 (dd, J = 8.2, 1.6 Hz, 1H), 4.68 (s, 2H).

¹³C NMR (101 MHz, CDCl₃) δ 198.2, 174.1, 144.2, 124.8, 123.1, 119.8, 114.1, 75.3.


HRMS (ESI) m/z: $[M + Na]^+$ Calcd for C₈H₅ClNaO₂ 190.9875; Found 190.9878.



¹**H NMR** (400 MHz, CDCl₃) δ 7.51 (dd, J = 8.4, 7.8 Hz, 1H), 7.03 (m, 2H), 4.66 (s, 2H).

¹³C NMR (101 MHz, CDCl₃) δ 196.7, 174.6, 138.0, 131.7, 123.1, 118.3, 112.1, 75.0.

HRMS (ESI) m/z: $[M + Na]^+$ Calcd for C₈H₅ClNaO₂ 190.9875; Found 190.9876.



85.0 mg, 95%, light yellow solid.

¹**H** NMR (400 MHz, CDCl₃) δ 8.61 (d, J = 2.5 Hz, 1H), 8.55 (dd, J = 9.1, 2.5 Hz, 1H), 7.33 – 7.26 (m, 1H), 4.85 (s, 2H).

¹³C NMR (101 MHz, CDCl₃) δ 197.2, 176.5, 143.0, 132.8, 121.5, 121.0, 114.4, 76.4.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₈H₆NO₄ 180.0296; Found 180.0292.




84.6 mg, 92%, white solid.

¹**H** NMR (400 MHz, CDCl₃) δ 8.79 (dq, J = 8.3, 0.9 Hz, 1H), 8.09 (d, J = 9.0 Hz, 1H), 7.86 (dt, J = 8.2, 0.9 Hz, 1H), 7.69 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H), 7.50 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H), 7.32 – 7.26 (m, 1H), 4.78 (s, 2H).

¹³C NMR (101 MHz, CDCl₃) δ 199.3, 176.7, 139.8, 129.9, 129.2, 129.1, 128.5, 125.5, 123.2, 114.0, 113.3, 75.5.


HRMS (ESI) m/z: $[M + H]^+$ Calcd for $C_{12}H_9O_2$ 185.0605; Found 180.0601.



¹**H NMR** (400 MHz, CDCl₃) δ 8.06 (dd, J = 8.4, 0.8 Hz, 1H), 7.74 (d, J = 8.4 Hz, 2H), 7.70 – 7.65 (m, 2H), 7.32 – 7.26 (m, 2H), 7.23 – 7.17 (m, 1H), 4.15 (s, 2H), 2.40 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 194.8, 153.6, 145.2, 137.3, 133.5, 130.1, 127.1, 125.0, 124.4, 124.0, 115.9, 56.1, 21.6.


HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₁₅H₁₄NO₃S 288.0699; Found 288.0695.



¹**H** NMR (400 MHz, CDCl₃) δ 7.95 (d, J = 8.5 Hz, 1H), 7.73 – 7.68 (m, 2H), 7.50 (dd, J = 8.5, 1.9 Hz, 1H), 7.44 (dt, J = 1.9, 0.9 Hz, 1H), 7.27 (d, J = 8.3 Hz, 2H), 4.12 (s, 2H), 2.39 (s, 3H), 2.37 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 194.9, 151.8, 145.0, 138.5, 134.2, 133.3, 130.0, 127.2, 125.2, 124.0, 115.9, 56.4, 21.6, 20.6.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₁₆H₁₆NO₃S 302.0852; Found 302.0857.




132.4 mg, 88%, light yellow solid.

¹**H** NMR (400 MHz, CDCl₃) δ 7.87 (dt, J = 1.5, 0.7 Hz, 1H), 7.75 – 7.70 (m, 2H), 7.54 (d, J = 7.9 Hz, 1H), 7.29 (d, J = 7.7 Hz, 2H), 7.01 (ddd, J = 7.9, 1.4, 0.7 Hz, 1H), 4.12 (s, 2H), 2.52 (s, 3H), 2.41 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 194.2, 154.0, 149.3, 145.1, 133.6, 130.1, 127.1, 125.6, 124.1, 122.9, 116.0, 56.4, 22.8, 21.6.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₁₆H₁₆NO₃S 302.0852; Found 302.0855.



¹**H** NMR (400 MHz, CDCl₃) δ 8.00 (dd, J = 9.1, 0.5 Hz, 1H), 7.71 – 7.65 (m, 2H), 7.34 – 7.24 (m, 3H), 7.05 (d, J = 2.7 Hz, 1H), 4.13 (s, 2H), 3.81 (s, 3H), 2.39 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 194.9, 156.8, 148.3, 145.1, 133.0, 130.1, 127.2, 126.6, 126.1, 117.7, 104.8, 56.7, 55.8, 21.6.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₁₆H₁₆NO₄S 318.0802; Found 318.0806.




122.0 mg, 80%, yellow solid.

¹**H** NMR (400 MHz, CDCl₃) δ 8.04 (dd, J = 9.1, 3.9 Hz, 1H), 7.68 (d, J = 8.1 Hz, 2H), 7.40 (td, J = 8.7, 2.8 Hz, 1H), 7.30 – 7.25 (m, 3H), 4.16 (s, 2H), 2.39 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 193.9 (d, J = 3.0 Hz), 160.6, 158.1, 149.9, 145.4, 133.1, 130.2, 127.2, 124.8 (d, J = 25.3 Hz), 117.7 (d, J = 8.1 Hz), 109.9 (d, J = 24.2 Hz), 56.8, 21.6.


HRMS (ESI) m/z: $[M + Na]^+$ Calcd for $C_{15}H_{12}FNNaO_3S$ 328.0423; Found 328.0426.



¹**H** NMR (400 MHz, CDCl₃) δ 8.02 (d, J = 8.8 Hz, 1H), 7.74 – 7.70 (m, 2H), 7.65 – 7.59 (m, 2H), 7.31 (d, J = 8.1 Hz, 2H), 4.17 (s, 2H), 2.42 (s, 3H).

¹³**C NMR** (101 MHz, CDCl₃) δ 193.4, 151.9, 145.5, 137.1, 133.1, 130.2, 130.1, 127.1, 126.3, 123.9, 117.2, 56.5, 21.6.


HRMS (ESI) m/z: $[M + Na]^+$ Calcd for C₁₅H₁₂ClNNaO₃S 344.0125; Found 344.0123.



¹**H NMR** (400 MHz, CDCl₃) δ 8.06 (d, J = 1.6 Hz, 1H), 7.73 (d, J = 8.2 Hz, 2H), 7.56 (d, J = 8.3 Hz, 1H), 7.32 (d, J = 8.1 Hz, 2H), 7.14 (dd, J = 8.2, 1.6 Hz, 1H), 4.14 (s, 2H), 2.41 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 193.3, 154.1, 145.6, 144.0, 133.3, 130.3, 127.1, 125.3, 124.8, 123.4, 116.0, 56.3, 21.6.


HRMS (ESI) m/z: $[M + Na]^+$ Calcd for C₁₅H₁₂ClNNaO₃S 344.0125; Found 344.0127.



¹**H NMR** (400 MHz, CDCl₃) δ 7.94 (d, J = 9.4 Hz, 1H), 7.74 (dq, J = 4.3, 2.1 Hz, 2H), 7.72 – 7.67 (m, 2H), 7.29 (d, J = 8.2 Hz, 2H), 4.14 (s, 2H), 2.40 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 193.2, 152.4, 145.5, 139.8, 133.2, 130.3, 127.1, 127.1, 126.7, 117.6, 117.3, 56.4, 21.6.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₁₅H₁₃BrNO₃S 365.9802; Found 365.9807.



¹**H** NMR (400 MHz, CDCl₃) δ 8.38 – 8.33 (m, 2H), 8.09 (dd, J = 8.6, 0.8 Hz, 1H), 7.78 – 7.74 (m, 2H), 7.34 – 7.30 (m, 2H), 4.23 (s, 2H), 3.94 (s, 3H), 2.42 (s, 3H).


¹³C NMR (101 MHz, CDCl₃) δ 193.7, 165.5, 156.2, 145.7, 138.3, 133.4, 130.3, 127.1, 126.5, 126.0, 124.9, 115.4, 56.6, 52.5, 21.6.

IR (neat): 2930, 1716, 1602, 1488, 1445, 1363, 1280, 1165, 1090, 1028, 913, 745, 662, 589, 545.


HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₁₇H₁₆NO₅S 346.0747; Found 346.0743.

4. Procedure for the preparation of compounds 7a-c and 8a'-c'


Compound 7a,⁶ $7b^7$ and $7c^8$ were prepared by reported procedures. **8a'-c'** were prepared by the same procedure as the preparation of coumaran-3-ones.



¹**H** NMR (400 MHz, CDCl₃) δ 7.58 - 7.50 (m, 2H), 7.46 - 7.42 (m, 1H), 7.39 - 7.35 (m, 3H), 7.32 - 7.28 (m, 1H), 7.02 - 6.98 (m, 1H), 6.92 (t, J = 7.6 Hz, 1H), 5.84 (br s, 1H). The data is in accordance with the literature.⁶




¹**H** NMR (400 MHz, CDCl₃) δ 7.68 (d, J = 8.3 Hz, 2H), 7.63 (d, J = 8.3 Hz, 1H), 7.49 - 7.45 (m, 2H), 7.42 - 7.36 (m, 4H), 7.32 - 7.27 (m, 1H), 7.20 (br s, 1H), 7.17 (d, J = 8.2 Hz, 2H), 7.07 (t, J = 7.6 Hz, 1H), 2.34 (s, 3H). The data is in accordance with the literature.⁷



363 mg, 84%, yellow solid.

¹**H NMR** (400 MHz, CDCl₃) δ 7.66 (d, J = 7.6 Hz, 2H), 7.57 (d, J = 8.4 Hz, 1H), 7.28 (bs, 1H), 7.22 - 7.17 (m, 4H), 6.96 (t, J = 8.0 Hz, 1H), 2.40 (t, J = 7.2 Hz, 2H), 2.33 (s, 3H), 1.60 - 1.54 (m, 2H), 1.50 - 1.40 (m, 2H), 0.96 (t, J = 7.6 Hz, 3H). The data is in accordance with the literature.⁸




8a', 92.2 mg, 95%, white solid.

¹**H** NMR (400 MHz, CDCl₃) δ 7.95 - 7.90 (m, 2H), 7.66 - 7.57 (m, 2H), 7.50 (t, J = 7.6 Hz, 2H), 7.44 - 7.25 (m, 3H), 7.08 - 7.05 (m, 1H).

¹³C NMR (101 MHz, CDCl₃) δ 156.0, 155.0, 130.6, 129.3, 128.8, 128.6, 125.0, 124.3, 123.0, 121.0, 111.2, 101.4.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₁₄H₁₁O 195.0810; Found 195.0814.




8b', 159.6 mg, 92%, yellow solid.

¹**H NMR** (400 MHz, CDCl₃) δ 8.38 (d, J = 8.4 Hz, 1H), 7.57 (dd, J = 7.2, 2.5 Hz, 2H), 7.53 - 7.48 (m, 4H), 7.42 (ddd, J = 8.5, 7.2, 1.4 Hz, 1H), 7.36 - 7.30 (m, 3H), 7.10 (d, J = 8.1 Hz, 2H), 6.61 (s, 1H), 2.35 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 144.5, 142.1, 138.3, 134.7, 132.4, 130.6, 130.3, 129.2, 128.6, 127.5, 126.8, 124.8, 124.3, 120.7, 116.7, 113.6, 21.5.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₂₁H₁₈NO₂S 348.1058; Found 348.1051.



8c', 142.2 mg, 87%, yellow solid.

¹**H NMR** (400 MHz, CDCl₃) δ 8.19 (d, J = 8.2 Hz, 1H), 7.64 (d, J = 8.3 Hz, 2H), 7.45 - 7.40 (m, 1H), 7.29 - 7.17 (m, 4H), 6.40 (s, 1H), 3.05 - 2.95 (m, 2H), 2.35 (s, 3H), 1.75 (p, J = 7.6 Hz, 2H), 1.46 (h, J = 7.4 Hz, 2H), 0.98 (t, J = 7.3 Hz, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 144.6, 142.5, 137.2, 136.3, 129.8, 129.7, 126.2, 123.7, 123.4, 120.0, 114.8, 108.6, 31.0, 28.7, 22.5, 21.5, 13.9.

HRMS (ESI) m/z: $[M + H]^+$ Calcd for C₁₉H₂₂NO₂S 328.1371; Found 328.1376.

5. References

(1) For compounds 2a-b, 2g-i and 2k, see: (a) Shu, C.; Liu, R.; Liu, S.; Li, J.-Q.; Yu, Y.-F.; He, Q.; Lu, X.; Ye, L.-W. *Chem. Asian J.* 2015, *10*, 91. For compound 2c, see: (b) Gonz aez, A. G.; Barrera, J. B.; Hern andez, C. Y. *Heterocycles* 1992, *34*, 1311. For compound 2e, see: (c) Jung, M. E.; Abrecht, S. *J. Org. Chem.* 1988, *53*, 423. For compound 2f, see: (d) Tomaszewski, Z.; Johnson, M. P.; Huang, X.; Nichols, D. E. *J. Med. Chem.* 1992, *35*, 2061. For compound 2j, see: (e) Mulholland, T. P. C.; Honeywood, R. I. W.; Preston, H. D.; Rosevear, D. T. *J. Chem. Soc.* 1965, 4939. For compound 2i, see: (f) Anderson, N. G.; Parvez, M.; Keay, B. A. *Org. Lett.* 2000, *2*, 2817. For compounds 6a-h, see: (g) Shu, C.; Li, L.; Xiao, X.-Y.; Yu, Y.-F.; Ping, Y.-F.; Zhou, J.-M.; Ye, L.-W. *Chem. Commun.* 2014, *50*, 8689. For compound 8a', see: (h) Duan, X.-F.; Zeng, J.; Zhang, Z.-B.; Zi, G.-F. *J. Org. Chem.* 2007, *72*, 10283. For compounds 8b' and 8c', see: (i) Yin, Y.; Ma, W.; Chai, Z.; Zhao, G. *J. Org. Chem.* 2007, *72*, 5731.

(2) Sahani, R. L.; Patil, M. D.; Wagh, S. B.; Liu, R.-S. Angew. Chem., Int. Ed., 2018, 57, 14878.

(3) Bucher, J.; Wurm, T.; Nalivela, K. S.; Rudolph, M.; Rominger F.; Hashmi, A. S. K. *Angew. Chem., Int. Ed.*, **2014**, *53*, 3854.


(4) Noyce, D. S.; Nichols, R. J. Org. Chem. 1972, 37, 4311.

(5) Beekman, A. M.; O'Connell, M. A.; Howell, L. A. Angew. Chem., Int. Ed., 2017, 56, 10446.

(6) Li, Y.; Gryn'ova, G.; Saenz, F.; Jeanbourquin, X.; Sivula, K.; Corminboeuf, C.; Waser, J. *Chem. Eur. J.* **2017**, *23*, 8058.

(7) Chong, E.; Blum, S. A. J. Am. Chem. Soc. 2015, 137, 10144.

(8) Liu, J.; Xie, X.; Liu, Y. Chem. Commun. 2013, 49, 11794.



6. ¹H NMR and ¹³C NMR Spectra

